List of Cardene drug patents

Cardene is owned by Chiesi.

Cardene contains Nicardipine Hydrochloride.

Cardene has a total of 5 drug patents out of which 0 drug patents have expired.

Cardene was authorised for market use on 30 January, 1992.

Cardene is available in injectable;injection, injectable;intravenous dosage forms.

Cardene can be used as method for treating acute elevations of blood pressure in human subject in need thereof.

The generics of Cardene are possible to be released after 26 December, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455524 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(4 years from now)

US7659291 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(4 years from now)

US10758616 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(4 years from now)

US7612102 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(4 years from now)

US9364564 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(4 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 1992

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INJECTION; INJECTABLE;INTRAVENOUS

How can I launch a generic of CARDENE before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic